Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Arginine Hydrochloride and Levamisole in Advanced HCC
NCT03950518Phase 3Unknown
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
- Start
- Apr 2019
- Primary completion
- Apr 2023
- Modality
- Peptides, Recombinant Proteins and Enzymes, Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of arginine and levamisole in hepatocellular carcinoma (HCC), sponsored by The First Affiliated Hospital of Zhengzhou University. Primary endpoint: Progression-free Survival at 24 months. Status: unknown.
02
Drugs
argininelevamisole
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT03950518.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03950518.